The Glycome of Normal and Malignant Plasma Cells
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
The glycome, i.e. the cellular repertoire of glycan structures, contributes to important functions such as adhesion and intercellular communication. Enzymes regulating cellular glycosylation processes are related to the pathogenesis of cancer including multiple myeloma. Here we analyze the transcriptional differences in the glycome of normal (n = 10) and two cohorts of 332 and 345 malignant plasma-cell samples, association with known multiple myeloma subentities as defined by presence of chromosomal aberrations, potential therapeutic targets, and its prognostic impact. We found i) malignant vs. normal plasma cells to show a characteristic glycome-signature. They can ii) be delineated by a lasso-based predictor from normal plasma cells based on this signature. iii) Cytogenetic aberrations lead to distinct glycan-gene expression patterns for t(11;14), t(4;14), hyperdiploidy, 1q21-gain and deletion of 13q14. iv) A 38-gene glycome-signature significantly delineates patients with adverse survival in two independent cohorts of 545 patients treated with high-dose melphalan and autologous stem cell transplantation. v) As single gene, expression of the phosphatidyl-inositol-glycan protein M as part of the targetable glycosyl-phosphatidyl-inositol-anchor-biosynthesis pathway is associated with adverse survival. The prognostically relevant glycome deviation in malignant cells invites novel strategies of therapy for multiple myeloma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among 243 glycogenes, 60 showed a significantly higher expression in MM than normal plasma cell samples, while 20 showed a lower one [141].”
From GANAB and N-Glycans Substrates Are Relevant in Human Physiology, Polycystic Pathology and Multiple Sclerosis: A Review (2022) · cites this paper as [141]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
A Model-Based Background Adjustment for Oligonucleotide Expression Arrays
Wu, Z., Irizarry, R. A., Gentleman, R., Martinez-Murillo, F., & Spencer, F. (2004) · Journal of the American Statistical Association · doi:10.1198/016214504000000683 · Cited by 1,716 · cited 1×
“Statistical analysis Expression data were gcrma-preprocessed [43] and log2 transformed.”
MethodBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Kyle, R. A., & Rajkumar, S. V. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041875 · Cited by 1,296
A global test for groups of genes: testing association with a clinical outcome
Goeman, J. J., van de Geer, S. A., de Kort, F., & van Houwelingen, H. C. (2004) · Bioinformatics · doi:10.1093/bioinformatics/btg382 · Cited by 1,069 · cited 1×
“So both approaches have slightly different objectives [47].”
BackgroundShaughnessy, J. D., Zhan, F., Burington, B. E., Huang, Y., Colla, S., Hanamura, I., Stewart, J. P., Kordsmeier, B., Randolph, C., Williams, D. R., et al. (2007) · Blood · doi:10.1182/blood-2006-07-038430 · Cited by 914
Avet-Loiseau, H., Attal, M., Moreau, P., Charbonnel, C., Garban, F., Hulin, C., Leyvraz, S., Michallet, M., Yakoub-Agha, I., Garderet, L., et al. (2007) · Blood · doi:10.1182/blood-2006-08-040410 · Cited by 911
Cited by
The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma
Glavey, S. V., Manier, S., Natoni, A., Sacco, A., Moschetta, M., Reagan, M. R., Murillo, L. S., Sahin, I., Wu, P., Mishima, Y., et al. (2014) · Blood · doi:10.1182/blood-2014-03-560862 · Cited by 134
“PSGL-1 is the predominant physiologic ligand for P-selectin and L-selectin, but when modified by HECA-452 reactive glycans (CLA), it can also serve as an E-selectin ligand.(24) Posttranslational modifications of PSGL-1 are important for optimal selectin binding; to bind to P-selectin, PSGL-1 requires ana-2,3-sialylate…”
BackgroundThe cancer glycome: Carbohydrates as mediators of metastasis
Glavey, S. V., Huynh, D., Reagan, M. R., Manier, S., Moschetta, M., Kawano, Y., Roccaro, A. M., Ghobrial, I. M., Joshi, L., & O'Dwyer, M. E. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.01.003 · Cited by 116
“has been defined and this has been associated to distinct cytogenetic abnormalities in this disease [158].”
BackgroundTibullo, D., Giallongo, C., Romano, A., Vicario, N., Barbato, A., Puglisi, F., Parenti, R., Amorini, A. M., Saab, M. W., Tavazzi, B., et al. (2020) · Biomolecules · doi:10.3390/biom10050696 · Cited by 69
“An increase in HBP-mediated protein O-glycosylation has also been found in the case of MM [52], although data in this type of cancer are not particularly abundant.”
BackgroundPolyclonal Immunoglobulin G N-Glycosylation in the Pathogenesis of Plasma Cell Disorders
Mittermayr, S., Le, G. N., Clarke, C., Millán‐Martín, S., Larkin, A., O’Gorman, P., & Bones, J. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00768 · Cited by 40
Computational Biology and Chemistry
Behzadi, P., & Bernabò, N. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.83539 · Cited by 40
Role of Galectins in Multiple Myeloma
Storti, P., Marchica, V., & Giuliani, N. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122740 · Cited by 35
“However, there are some evidences that MM cells may change their glycome during the malignant transformation from normal PCs; this aspect deserve to be considered in a possible therapeutic context because changes on some tumor glycoproteins on MM cells surfaces, such as mucin-1, could lead to different affinity to gal…”
Friedel, M., André, S., Goldschmidt, H., Gabius, H., & Schwartz‐Albiez, R. (2016) · Glycobiology · doi:10.1093/glycob/cww066 · Cited by 30
Self-citationKunej, T. (2019) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2019.0149 · Cited by 30
“Cytogenetic aberrations t(11;14), t(4;14), hyperdiploidy, 1q21 gain, and 13q14 deletion have been associated with glycogene expression patterns in multiple myeloma (Moehler et al., 2013).”
De Masi, R., & Orlando, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137373 · Cited by 20
“Among 243 glycogenes, 60 showed a significantly higher expression in MM than normal plasma cell samples, while 20 showed a lower one [141].”
Backgroundda Fonseca, L. M., da Silva, V. A., da Costa, K. M., dos Reis, J. S., Previato, J. O., Mendonça‐Previato, L., & Freire‐de‐Lima, L. (2022) · Glycoconjugate Journal · doi:10.1007/s10719-022-10042-2 · Cited by 16
“It has been known for over fifty years that changes in the glycosylation pattern of proteins and lipids are characteristics of cancer cells [20, 21].”
BackgroundGalectin-9 – ligand axis: an emerging therapeutic target for multiple myeloma
Shil, R. K., Mohammed, N. B. B., & Dimitroff, C. J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1469794 · Cited by 15
Pei, H., Chen, Y., Wu, F., Zhang, Y., Zhang, X., Li, J., Pan, L., Chen, Y., & Huang, Y. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16739 · Cited by 8
“23 Through this study, we obtained fi ve candidate genes ( PIGM , PIGA , EGR1 , PIGK , and PIGL ) and enriched them with GO and KEGG.”
Role of PIGM and PIGX in glycosylphosphatidylinositol biosynthesis and human health (Review)
Torres‐Valdetano, Á., Vallejo‐Ruiz, V., Milflores‐Flores, L., & Martínez‐Morales, P. (2024) · Biomedical Reports · doi:10.3892/br.2024.1746 · Cited by 4
“Analysis in myeloma showed that high expression of PIGM is associated with adverse survival outcomes (37).”
BackgroundInfluentialSystems Glycobiology: Past, Present, and Future
Yıldız, S. Y. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92267 · Cited by 3
“In the further studies, myeloma was compared with normal plasma cell samples and 60 upregulated and 20 downregulated genes were found among 243 genes in glycan-biosynthesis pathway [54].”
BackgroundSample size determination for training cancer classifiers from microarray and RNA-seq data
Safo, S. E., Song, X., & Dobbin, K. K. (2015) · The Annals of Applied Statistics · doi:10.1214/15-aoas825 · Cited by 1
“Regularized regression methods, such as the lasso, are common in the analysis of high-dimensional data [Bi et al. (2014), Moehler et al. (2013), Zhang et al. (2013), Zwiener et al. (2014)].”
MethodExploring the Protein Glycosylation Pathways to Find New Therapeutic Alternatives
Mora-Montes, H. M. (2015) · Journal of Glycobiology · doi:10.4172/2168-958x.1000e108
“It has been established that cancer cells have dysregulation of glycosylation pathways, and differentially express secreted and membrane glycoproteins [10,11].”
BackgroundMultiple myeloma: The role of glycosylation in disease development and progression.
Glavey, S. V. (2017) · Arrow@dit (Dublin Institute of Technology) · doi:10.13025/16076
Design and analysis issues in high dimension, low sample size problems
Safo, S. E. (2014)
Metadata
- Authors
- Moehler, T. M., Seckinger, A., Hose, D., Andrulis, M., Moreaux, J., Hielscher, T., Willhauck-Fleckenstein, M., Merling, A., Bertsch, U., Jauch, A., Goldschmidt, H., Klein, B., & Schwartz-Albiez, R.
- Affiliations
- German Cancer Research Center (DE)
- University Hospital Heidelberg (DE)
- Heidelberg University (DE)
- Inserm (FR)
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-12-26
- Volume
- 8
- Issue
- 12
- Pages
- e83719
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3873332
- OpenAlex
- W2067873319
- Cited by
- 17
- References
- 56
- Citations by year
- 2024: 3 · 2022: 2 · 2020: 2 · 2019: 2 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 2
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Leuka
- Deutsche Forschungsgemeinschaft (SFB/TR79)
- Institut National de la Santé et de la Recherche Médicale
- Bundesministerium für Bildung und Forschung
- José Carreras Leukämie-Stiftung
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- glycome, multiple myeloma, malignant plasma cells, glycosylation, hyperdiploidy, 1q21 gain, 13q14 deletion, chromosomal abnormalities, prognostic factors, survival prediction, autologous stem cell transplantation, high-dose melphalan, therapeutic target
- MeSH terms
- Gene Expression Regulation, Heparan Sulfate, Humans, Mannosyltransferases, Multiple Myeloma, Plasma Cells, Polysaccharides, Cluster Analysis, Glycosylphosphatidylinositols, Gene Dosage, Gene Expression Profiling, Metabolic Networks and Pathways, Glycomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.